| Species |
Cynomolgus |
| Protein Construction |
| His |
CD10/MME (Asp53-Trp750)
Accession # G7NZK8 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave the fluorogenic peptide substrate, McaRPPGFSAFK (Dnp) OH. The specific activity is > 1200 pmoles/min/μg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
80.69 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 81-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD10 is an endopeptidase that degrades various bioactive peptides in the extracellular matrix. In addition to enzymatic degradation, it affects multiple intracellular signal transduction pathways. CD10 expression has been extensively studied in human epithelial cancers of numerous organs and sites. CD10 expression pattern depended on the histotypes of thyroid lesions. When possible metastatic tumours and non-epithelial tumours are excluded, high CD10 expression may be useful in determining whether a primary thyroid carcinoma includes an anaplastic component. |
| Synonyms |
Neprilysin; Atriopeptidase; Enkephalinase; NEP; Neutral; SFE; CD10; MME; CALLA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
